The rationale of using GLUT-inhibitors to recreate the pathology of AD in this cell based model is justified because multiple post-mortem studies on the AD brain indicated decreased levels of GLUT1, GLUT3 and GLUT4 as summarized in a recent review [5]. This evidence concerns the gene SLC2A4 and Alzheimer disease.